abstract |
The present invention relates to antibodies specifically binding to HER2 / neu with reduced glycosylation compared to known 4D5 antibodies, particularly chimeric 4D5 antibodies to HER2 / neu. The invention also relates to methods of using 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and treatment of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious diseases. |